*The flexibility to adjust dose based on your clinical judgment and patient presentation.
Find out how RINVOQ’s flexible* dosing regimen can support your patients – explore the resources below.
*The flexibility to adjust dose based on your clinical judgment and patient presentation.
The recommended dose of RINVOQ is:
– 15 mg once daily for adults.
– 15 mg once daily for adolescents (from 12 to 17 years of age) weighing at least 40 kg.†
†RINVOQ has not been studied in adolescents weighing less than 40 kg.2
In adults aged <65 years, the dose may be increased to 30 mg once daily from 4 weeks after initiation of treatment, if clinically warranted and based on benefit-risk assessment.
For patients ≥65 years of age, treatment with 30 mg is not recommended.
The lowest effective dose for maintenance should be considered.
RINVOQ should be ceased if a satisfactory clinical response is not achieved after 16 weeks.
With/without TCS1-3
Tablet cannot be crushed, split or chewed
Taken with or without food
Taken at any time of day
FIND OUT MORE ABOUT RINVOQ
REFERENCES
- Guttman-Yassky E et al. Lancet 2021; DOI: 10.1016/S0140-6736.
- RINVOQ Approved Product Information.
- Reich K et al. Lancet 2021;397(10290):2169–2181.
WARNING: Based on the results from a post-marketing safety study of another JAK inhibitor, RINVOQ should only be used if no suitable treatment alternatives are available in patients: Refer to Product Information. |
PBS Information
RINVOQ: Authority required. Refer to PBS Schedule for full authority information. This product is not listed on the PBS for the treatment of Crohn’s disease.
Please review the full Product Information (PI) before prescribing, available below.
AU-ABBV-210079. August 2023